PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33808599-4 2021 This is the case of IDH1/2 mutations generating the abnormal conversion of alpha-ketoglutarate (KG) to 2-hydroxyglutarate, an oncometabolite inhibiting KG-dependent enzymes, such as the TET family of genes (pivotal in characterizing leukemia cells either by mutations, e.g., TET2, or by altered expression, e.g., TET1/2/3). tetramethylenedisulfotetramine 186-189 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 20-26 31225434-2 2017 The inhibition of TET enzymes by D-2-hydroxyglutarate (D-2-HG), which is produced by mutant IDH1/2 (mIDH1/2), has been suggested to promote epigenetic deregulation during tumorigenesis. tetramethylenedisulfotetramine 18-21 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 92-98 34336831-2 2021 Mutations targeting genes encoding DNA methyltransferase (DNMT), TET family of DNA demethylases, and isocitrate dehydrogenase (IDH1, IDH2) that produce TET inhibitory metabolite, 2-hyoxyglutarate (2-HG), are found in more than half of acute myeloid leukemia (AML). tetramethylenedisulfotetramine 152-155 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 127-131 34661153-3 2021 They show that, in the context of the myelocytic/granulocytic lineage, TFEB acts as a tumor suppressor by inducing the IDH1/2-TET pathway, which in turn, leads to altered DNA methylation and increased expression of genes involved in myeloid differentiation and apoptosis. tetramethylenedisulfotetramine 126-129 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 119-123 34873300-3 2022 These regions had modest hypermethylation in AMLs with biallelic TET2 mutations, and levels of 5-hydroxymethylation that were diminished in IDH and TET-mutant samples, indicating that this hypermethylation results from inhibition of TET-mediated demethylation. tetramethylenedisulfotetramine 233-236 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 140-143 27548812-11 2016 Consistent with this result, overexpression of IDH1/2 mutants also inhibited TET catalytic domain-promoted oxidation of RNA. tetramethylenedisulfotetramine 77-80 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 47-53 27548812-12 2016 In this study, we show not only the enrichment of 5hmC in mRNA, but also a regulatory mechanism of RNA 5hmC-IDH1/2 mutations inhibit TET-promoted RNA 5hmC, which suggests an involvement of IDH1/2 mutations in tumorigenesis through the deregulation of RNA biology. tetramethylenedisulfotetramine 133-136 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 108-114 27548812-12 2016 In this study, we show not only the enrichment of 5hmC in mRNA, but also a regulatory mechanism of RNA 5hmC-IDH1/2 mutations inhibit TET-promoted RNA 5hmC, which suggests an involvement of IDH1/2 mutations in tumorigenesis through the deregulation of RNA biology. tetramethylenedisulfotetramine 133-136 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 189-195 27548812-0 2016 IDH1/2 Mutants Inhibit TET-Promoted Oxidation of RNA 5mC to 5hmC. tetramethylenedisulfotetramine 23-26 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 0-4 27548812-4 2016 Here, we show that 5hmC is enriched in mRNA, and IDH1/2 mutants inhibit TET-promoted oxidation of RNA 5mC to 5hmC. tetramethylenedisulfotetramine 72-75 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 49-55 27548812-5 2016 Since IDH1/2 mutations have been described to block the DNA oxidative activity of TETs, we hypothesized that IDH1/2 mutations might also inhibit the RNA oxidative activity of TETs. tetramethylenedisulfotetramine 82-86 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 6-12 27548812-5 2016 Since IDH1/2 mutations have been described to block the DNA oxidative activity of TETs, we hypothesized that IDH1/2 mutations might also inhibit the RNA oxidative activity of TETs. tetramethylenedisulfotetramine 82-86 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 109-115 27548812-5 2016 Since IDH1/2 mutations have been described to block the DNA oxidative activity of TETs, we hypothesized that IDH1/2 mutations might also inhibit the RNA oxidative activity of TETs. tetramethylenedisulfotetramine 175-179 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 6-12 27548812-5 2016 Since IDH1/2 mutations have been described to block the DNA oxidative activity of TETs, we hypothesized that IDH1/2 mutations might also inhibit the RNA oxidative activity of TETs. tetramethylenedisulfotetramine 175-179 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 109-115 27548812-10 2016 Further study indicated that IDH1/2 mutants showed significant ability to inhibit TET-promoted RNA5hmC. tetramethylenedisulfotetramine 82-85 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 29-35 24386123-12 2013 Finally, mutations of IDH1 (IDH1 (R132)) and IDH2 (IDH2 (R172)) leading to production of the TET inhibiting oncometabolite 2-hydroxyglutarate in germ cell cancer cell lines were not detected. tetramethylenedisulfotetramine 93-96 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 22-26 24386123-12 2013 Finally, mutations of IDH1 (IDH1 (R132)) and IDH2 (IDH2 (R172)) leading to production of the TET inhibiting oncometabolite 2-hydroxyglutarate in germ cell cancer cell lines were not detected. tetramethylenedisulfotetramine 93-96 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 28-32 23863747-3 2013 Here we show that the IDH variants in CS are also associated with a hypermethylation phenotype and display increased production of the oncometabolite 2-hydroxyglutarate, supporting the role of mutant IDH-produced 2-hydroxyglutarate as an inhibitor of TET-mediated DNA demethylation. tetramethylenedisulfotetramine 251-254 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 22-25 23863747-3 2013 Here we show that the IDH variants in CS are also associated with a hypermethylation phenotype and display increased production of the oncometabolite 2-hydroxyglutarate, supporting the role of mutant IDH-produced 2-hydroxyglutarate as an inhibitor of TET-mediated DNA demethylation. tetramethylenedisulfotetramine 251-254 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 200-203